共 50 条
- [31] Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (12): : 1195 - 1202
- [35] Estetrol (E4), a Promising New Treatment for Menopausal Vasomotor Symptoms: Beneficial Lipid and Carbohydrate Metabolism in a Phase 3 Randomized, Double-blind, Placebo-Controlled Trial [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1259 - 1259
- [36] Efficacy and Safety of Estetrol (E4), a Promising New Treatment for Menopausal Vasomotor Symptoms: Results of Two Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1454 - 1454
- [37] Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
- [39] Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2877 - 2884